The jury verdict yesterday came after the finding that Boston Scientific’s Synergy BP drug-eluting stents infringed on TissueGen and the university’s IP.
The patent under question arose out of research that TissueGen co-founder Kevin Nelson, PhD, conducted at the University of Texas Arlington in the late 1990s. Filed in 2000, the patent was for a “drug-releasing biodegradable fiber implant.”
The amended lawsuit complaint explained how Nelson came up with the idea:
“Though the industry believed otherwise, Dr. Nelson believed in the commercial viability of a drug-eluting stent based on biodegradable polymer fibers capable of controlled release of sensitive therapeutics. Dr. Nelson came up with the idea for his drug-eluting stent innovation while investigating wa…